Last updated: 2026-10-11 12:44:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
DaVita Inc. (DVA) operates in the SERVICES-MISC HEALTH & ALLIED SERVICES, NEC sector and is listed on NYSE. The stock is currently priced at $179.19, with a market capitalization of $11.44B and a P/E ratio of 13.49. Over the past 52 weeks, its price has ranged from $101.00 to $247.49. This page covers its latest market performance, valuation, price trends and company information.
$11.44B | |
$177.00 | |
$247.49 | |
$10.22 | |
$177.02 | |
247.48K | |
762.80K | |
13.49 | |
$247.49 | |
$101.00 | |
-- | |
-- |
DaVita Inc. (DVA) last closed at $177.02 as of 2026-10-09 23:57:00, unchanged from the previous close of $177.02.
During the latest regular trading session, DVA traded between $10.22 and $247.49, with a volume of 247.48K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, DaVita Inc. (DVA) moved from $176.35 to $179.19, representing a gain of 1.61% ($2.84).
The stock traded between $173.95 and $182.61 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 504.87 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 53.4%
DVA is currently trading at $179.19, placing it 53.4% of the way from its 52-week low of $101.00 to its 52-week high of $247.49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
| Industry | SERVICES-MISC HEALTH & ALLIED SERVICES, NEC |
| Employees | 78000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of DaVita Inc. (DVA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.